#China #Suzhou #Bladder Cancer #ImmVira #MVR-T3011

ImmVira's Latest Milestone in Bladder Cancer Treatment

ImmVira Group, a forward-thinking biotechnology firm, has made headlines with their groundbreaking findings from the Phase IIa clinical trial of MVR-T3011, an innovative oncolytic immunotherapy candidate, revealed at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The clinical data, cut off on January 31, 2026, highlights an astounding 100% complete response rate (CRR) for patients battling BCG-unresponsive carcinoma in situ (CIS) and a significant 90% recurrence-free survival (RFS) rate in papillary tumors (Ta/T1).

Despite the standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) being the intravesical instillation of Bacillus Calmette-Guérin (BCG), shortages and high non-response rates leave many patients lacking adequate treatment options. Recognizing this gap, ImmVira’s MVR-T3011 is designed to directly induce robust local and systemic anti-tumor immunity specifically within the bladder, providing hope for those in dire need of alternative therapies.

Clinical Trial Highlights

The ongoing clinical trial includes a total of 46 participants who have been pathologically confirmed as having BCG-unresponsive high-risk NMIBC. The patients have been treated with MVR-T3011 via intravesical administration at two different dose levels:

• - Lower-dose group (2×10^9 PFU): Induction followed by maintenance dosing over two years.
• - Higher-dose group (1×10^10 PFU): Induction followed by maintenance dosing across the same time frame.

The results from the clinical trial are promising, showcasing significant clinical efficacy and safety across both CIS and papillary disease states. In particular, those in the higher-dose cohort demonstrated a 100% CRR at 3, 6, and 9 months, outperforming the lower-dose group that showed only a 66.7% CRR. Moreover, as follow-up is ongoing, the 12-month CRR for the higher dose cohort remains to be documented, but expectations are high.

Additionally, the papillary cohort saw a robust 12-month RFS of 74% for the lower-dose and an impressive 90% RFS at 9 months for the higher-dose group, reinforcing the treatment's effectiveness.

Safety and Efficacy

Across all 46 patients, MVR-T3011 revealed a manageable safety profile consistent with previous observations in similar treatments. Notably, no Grade 4 or 5 treatment-emergent adverse events were reported, emphasizing the safety of this new therapy.

Dr. Grace Zhou, Chairwoman and CEO of ImmVira, expressed her enthusiasm regarding these findings, referencing them as significant for the broader NMIBC community.